Repligen (RGEN) reported $738M in revenue for fiscal 2025, +16.4% year on year. That ranks #1968 by revenue among 2853 SEC filers and #187 in Healthcare. Net income was $48.9M, a net margin of 6.6%. Revenue has grown 21.0% a year on average since 2012 ($62.3M then). The fiscal 2025 balance sheet shows $2.9B in total assets, $566M in cash and $542M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerIncludingAssessedTax | $738M | +16.4% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $55.2M | +$90.3M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $48.9M | +$74.4M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $117M | −33.1% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $23.5M | −8.4% | FY20252025-12-31 |
| Total assetsAssets | $2.9B | +4.2% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $2.1B | +6.8% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $566M | −25.3% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $542M | +3.2% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $194M | $8.3M | Open → |
| Q2 20262026-06-30 | $204M | $5.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Repligen Corp
- Ticker
- RGEN
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0000730272
Filings
- 10-QJul 29, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Corcept TherapeuticsCORT | $761M | $99.7M |
| Irhythm HoldingsIRTC | $747M | −$45.0M |
| Emergent BiosolutionsEBS | $743M | $52.6M |
| RepligenRGEN | $738M | $48.9M |
| Pacira BiosciencesPCRX | $726M | $7.0M |
| Amphastar PharmaceuticalsAMPH | $720M | $98.1M |
| Supernus PharmaceuticalsSUPN | $719M | −$38.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Repligen — Key figures |url=https://companiesranked.com/en/company/repligen |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Repligen — Key figures. CompaniesRanked. https://companiesranked.com/en/company/repligenBibTeX
@misc{companiesranked-en-company-repligen-2026,
author = {{CompaniesRanked}},
title = {{Repligen — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/repligen}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-076528 · February 26, 2026
{{cite web |title=Repligen — Key figures — 10-K (0001193125-26-076528) |url=https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/rgen-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.